Yasmeen Rahimi

Q: How accurate are Yasmeen Rahimi's stock ratings?

About 34% of Yasmeen's ratings were profitable over a one-year hold, with an average return of -5.8% per rating, measured by 13Foresight from historical prices.

Q: How is Yasmeen ranked?

Yasmeen Rahimi is ranked #1723 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Piper Sandler

Wall Street Analyst

★★★☆☆

#1723

on 13Foresight · ranked by our own returns

36%

Success Rate

-6.4%

Average Return

49 of 136 calls profitable · -11.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 36% of Yasmeen Rahimi's ratings turned a profit when each position was held for 2 year — averaging -6.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

198 Buy 6 Hold 0 Sell

Yasmeen's Stock Coverage 63 ratings · 2026-11-09

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
TNYA Tenaya Therapeutics	Oct 30, 2026	BUY	Strong Buy +2621.8% avg upside 11 analysts	$40.00 10787.37% Upside	+0.0%	·
CLYM Climb Bio	Oct 30, 2026	BUY	Strong Buy +120.8% avg upside 21 analysts	$40.00 290.18% Upside	-13.5%	·
TECX Tectonic Therapeutic	Oct 29, 2026	BUY	Strong Buy +176.5% avg upside 24 analysts	$76.00 284.31% Upside	+0.7%	·
LBRX LB Pharmaceuticals, Inc.	Oct 28, 2026	BUY	Strong Buy +47.7% avg upside 11 analysts	$78.00 96.50% Upside	-4.4%	·
SVRA Savara	Oct 26, 2026	BUY	Strong Buy +80.0% avg upside 17 analysts	$16.00 231.87% Upside	-3.1%	·
LXRX Lexicon Pharmaceuticals	Oct 26, 2026	BUY	Buy +216.5% avg upside 10 analysts	$6.00 322.55% Upside	+2.1%	·
IVA Inventiva	Oct 23, 2026	BUY	Strong Buy +350.3% avg upside 17 analysts	$26.00 612.32% Upside	+1.4%	·
NKTR Nektar Therapeutics	Oct 22, 2026	BUY	Strong Buy +97.1% avg upside 26 analysts	$192.00 393.93% Upside	-3.6%	·
PRAX Praxis Precision Medicines	Oct 22, 2026	BUY	Strong Buy +99.2% avg upside 25 analysts	$1200.00 319.69% Upside	+7.2%	·
TRAX First Tracks Biotherapeutics Inc	Oct 20, 2026	BUY	Strong Buy +64.6% avg upside 11 analysts	$95.00 110.71% Upside	+18.9%	·
AGMB AgomAb Therapeutics NV ADR	Oct 14, 2026	BUY	Strong Buy +353.9% avg upside 8 analysts	$60.00 701.12% Upside	-21.2%	·
EWTX Edgewise Therapeutics	Oct 13, 2026	BUY	Strong Buy +18.0% avg upside 16 analysts	$51.00 31.11% Upside	+7.1%	·
ZURA Zura Bio	Oct 07, 2026	BUY	Strong Buy +292.3% avg upside 13 analysts	$26.00 543.47% Upside	-5.5%	·
ORKA Oruka Therapeutics	Oct 07, 2026	BUY	Strong Buy +37.2% avg upside 16 analysts	$180.00 85.87% Upside	+29.4%	·
EQ Equillium	Oct 06, 2026	BUY	Strong Buy +585.1% avg upside 16 analysts	$20.00 1359.79% Upside	-3.9%	·
KRRO Korro Bio	Oct 06, 2026	BUY	Buy +90.0% avg upside 19 analysts	$30.00 109.48% Upside	+51.1%	·
STTK Shattuck Labs	Oct 02, 2026	BUY	Strong Buy +276.2% avg upside 16 analysts	$15.00 169.86% Upside	-31.4%	·
DRUG Bright Minds Biosciences	Oct 01, 2026	BUY	Strong Buy +162.4% avg upside 11 analysts	$220.00 300.07% Upside	-57.9%	·
AVTX Avalo Therapeutics	Oct 01, 2026	BUY	Strong Buy +561.5% avg upside 20 analysts	$60.00 736.74% Upside	-53.6%	·
PALI Palisade Bio	Sep 23, 2026	BUY	Strong Buy +2087.9% avg upside 16 analysts	$25.00 2055.25% Upside	-29.4%	·
IMVT Immunovant	Sep 21, 2026	BUY	Strong Buy +38.4% avg upside 25 analysts	$66.00 126.35% Upside	-23.6%	·
TENX Tenax Therapeutics	Sep 15, 2026	BUY	Buy +1239.3% avg upside 9 analysts	$14.00 682.10% Upside	-7.6%	·
ROIV Roivant Sciences	Aug 28, 2026	BUY	Strong Buy +10.7% avg upside 19 analysts	$40.00 8.45% Upside	+12.0%	·
PRTA Prothena	Aug 07, 2026	BUY	Buy +195.1% avg upside 14 analysts	$36.00 324.95% Upside	-9.9%	·
GPCR Structure Therapeutics, Inc. Sponsored ADR	Aug 07, 2026	BUY	Strong Buy +373.2% avg upside 17 analysts	$93.00 325.19% Upside	-64.1%	·
ALGS Aligos Therapeutics	Aug 07, 2026	BUY	Strong Buy +860.4% avg upside 11 analysts	$175.00 3545.84% Upside	-19.3%	·
CYTK Cytokinetics	Aug 07, 2026	BUY	Strong Buy +43.4% avg upside 36 analysts	$107.00 69.78% Upside	-28.0%	·
BIOA BioAge Labs, Inc.	Aug 06, 2026	BUY	Strong Buy +506.9% avg upside 9 analysts	$73.00 1143.55% Upside	-50.8%	·
NAMS NewAmsterdam Pharma Company	Aug 04, 2026	BUY	Strong Buy +136.0% avg upside 19 analysts	$60.00 199.13% Upside	-31.4%	·
ANAB AnaptysBio	Jul 21, 2026	BUY	Strong Buy +48.7% avg upside 26 analysts	$93.00 92.65% Upside	-13.6%	·
ATYR aTyr Pharma	Jul 16, 2026	BUY	Buy +69.8% avg upside 17 analysts	$7.00 41.79% Upside	·	·
TVRD Tvardi Therapeutics	Jul 08, 2026	BUY	Strong Buy +2090.0% avg upside 24 analysts	$13.00 1539.73% Upside	-83.9%	·
MDGL Madrigal Pharmaceuticals	Jun 29, 2026	BUY	Strong Buy +20.2% avg upside 34 analysts	$900.00 109.19% Upside	-24.2%	·
UPB Upstream Bio, Inc.	Jun 25, 2026	BUY	Strong Buy +774.9% avg upside 9 analysts	$75.00 2099.34% Upside	-41.8%	·
UNCY Unicycive Therapeutics	Jun 01, 2026	BUY	Strong Buy +1285.0% avg upside 10 analysts	$90.00 2306.34% Upside	-52.8%	·
DSGN Design Therapeutics	May 27, 2026	BUY	Strong Buy +66.1% avg upside 9 analysts	$20.00 87.28% Upside	-8.0%	·
PLRX Pliant Therapeutics	May 12, 2026	BUY	Buy +2494.6% avg upside 21 analysts	$3.00 249.22% Upside	-31.4%	·
GOSS Gossamer Bio	Mar 18, 2026	BUY	Buy +1287.3% avg upside 17 analysts	$1200.00 11460.61% Upside	·	·
ARCT Arcturus Therapeutics	Mar 04, 2026	BUY	Buy +175.7% avg upside 36 analysts	$25.00 126.75% Upside	+36.5%	·
BNTC Benitec Biopharma	Sep 24, 2025	BUY	Strong Buy +171.7% avg upside 15 analysts	$30.00 243.27% Upside	-32.3%	·
ALT Altimmune	Jun 27, 2025	BUY	Strong Buy +1191.4% avg upside 20 analysts	$25.00 1125.40% Upside	-41.7%	·
SGMT Sagimet Biosciences, Inc. Class A	Jun 17, 2025	BUY	Strong Buy +194.3% avg upside 17 analysts	$67.00 575.48% Upside	+42.3%	·
IMUX Immunic	Mar 20, 2025	BUY	Strong Buy +399.8% avg upside 23 analysts	$28.00 272.88% Upside	-32.0%	·
OKUR OnKure Therapeutics	Dec 14, 2023	HOLD	Strong Buy +743.5% avg upside 13 analysts	$40.00 1426.80% Upside	-77.1%	·
PTGX Protagonist Therapeutics	Jul 05, 2023	BUY	Strong Buy -17.0% avg upside 19 analysts	$35.00 75.81% Downside	+118.3%	·
ENTA Enanta Pharmaceuticals	May 09, 2023	BUY	Buy +206.4% avg upside 17 analysts	$87.00 712.36% Upside	-79.3%	·
MIRM Mirum Pharmaceuticals	May 08, 2023	BUY	Strong Buy +48.1% avg upside 24 analysts	$77.00 9.42% Downside	+71.6%	·
AMRN Amarin	Mar 15, 2022	BUY	Hold -28.6% avg upside 18 analysts	$19.00 56.98% Upside	-70.0%	·
VXRT Vaxart	Feb 28, 2022	BUY	Strong Buy +1714.0% avg upside 8 analysts	$18.00 4086.08% Upside	-74.4%	·
VIP Vulcan Infrastructure and Power	Oct 12, 2021	HOLD	Hold +671.5% avg upside 5 analysts	—	·	·
MTNB Matinas BioPharma	Sep 13, 2021	HOLD	Buy +817.2% avg upside 7 analysts	$0.90 40.43% Downside	·	·
MRNA Moderna	Jun 03, 2020	BUY	Hold -48.5% avg upside 38 analysts	$68.00 69.43% Downside	+129.0%	·
DARE Daré Bioscience	May 15, 2020	BUY	Strong Buy +1692.2% avg upside 15 analysts	$4.00 471.76% Upside	+2.9%	·
EOCN Eocene	May 14, 2020	BUY	Buy +688.3% avg upside 13 analysts	$33.00 964.50% Upside	·	·
TPST Tempest Therapeutics	May 08, 2020	BUY	Buy +4215.3% avg upside 18 analysts	$6.00 1110.84% Upside	·	·
HEPA Hepion Pharmaceuticals	Mar 20, 2020	BUY	Strong Buy +27280.9% avg upside 9 analysts	$9.00 4900.01% Upside	·	·
FR:GNFT Genfit	Dec 19, 2019	BUY	Strong Buy +176.2% avg upside 5 analysts	$70.00 544.47% Upside	-72.6%	·
EVFM Evofem Biosciences	Dec 18, 2019	BUY	Buy +381150.0% avg upside 8 analysts	$12.00 199900.05% Upside	·	·
LRMR Larimar Therapeutics	Sep 06, 2019	HOLD	Strong Buy +621.1% avg upside 22 analysts	—	+77.1%	·
SEELQ Seelos Therapeutics	Aug 02, 2019	BUY	Buy +4638571328.5% avg upside 10 analysts	$8.00 799999899.96% Upside	·	·
MTVA MetaVia	Aug 10, 2018	HOLD	Strong Buy +2567.6% avg upside 13 analysts	$2.00 78.64% Upside	·	·
YARW Yarrow Bioscience	Jul 24, 2018	BUY	Strong Buy +38.6% avg upside 9 analysts	$29.00 45.77% Upside	·	·
GALT Galectin Therapeutics	Jan 04, 2018	BUY	Strong Buy +193.7% avg upside 8 analysts	$8.00 140.89% Upside	-32.2%	·

🔒 58 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Yasmeen Rahimi — Frequently Asked Questions

How accurate are Yasmeen Rahimi's stock ratings?

Based on the calls 13Foresight could measure, about 34% of Yasmeen's ratings were profitable over a one-year hold, with an average return of -5.8% per rating, or +23.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Yasmeen ranked on 13Foresight?

Yasmeen Rahimi is currently ranked #1723 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Yasmeen cover?

Yasmeen most recently has ratings on TNYA, CLYM, TECX, LBRX, SVRA, LXRX, IVA, NKTR, PRAX, TRAX, AGMB, EWTX and 51 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Yasmeen Rahimi

Rating Distribution

Welcome to 13Foresight!